CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Dexamethasone Phosphate Ophthalmic +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01602068
NCT01602068Phase 2Completed

A Prospective, Multi-Center, Randomized, Double-Masked, Negative-Controlled Clinical Trial Designed to Compare the Safety and Efficacy of EGP-437 (Dexamethasone Phosphate Ophthalmic Solution) Delivered by EyeGate® II Iontophoresis to Placebo in Patients Undergoing Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens

Eyegate Pharmaceuticals, Inc.·interventional·Posted May 18, 2012·Updated Jan 29, 2019

In Brief

A Phase 2 clinical trial evaluating Dexamethasone Phosphate Ophthalmic and 100 mM Sodium Citrate Buffer for Cataract. Completed, enrolled 45 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to placebo in patients undergoing cataract surgery with implantation of a posterior chamber intraocular lens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 18, 2012
Enrollment StartMay 1, 2012
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.1 years ago

Interventions

Dexamethasone Phosphate Ophthalmicdrug

Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)

100 mM Sodium Citrate Bufferdrug

Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution